132 related articles for article (PubMed ID: 38340425)
21. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
[TBL] [Abstract][Full Text] [Related]
22. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Zhang Y; Laterra J; Pomper MG
Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
[TBL] [Abstract][Full Text] [Related]
23. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
24. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
Sodani K; Patel A; Anreddy N; Singh S; Yang DH; Kathawala RJ; Kumar P; Talele TT; Chen ZS
Biochem Pharmacol; 2014 May; 89(1):52-61. PubMed ID: 24565910
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
26. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
27. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
28. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
[TBL] [Abstract][Full Text] [Related]
30. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
[TBL] [Abstract][Full Text] [Related]
31. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J
BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205
[TBL] [Abstract][Full Text] [Related]
32. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
[TBL] [Abstract][Full Text] [Related]
33. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
34. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
36. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
J Cell Physiol; 2020 Sep; 235(9):6230-6245. PubMed ID: 32017076
[TBL] [Abstract][Full Text] [Related]
37. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
38. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
39. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
40. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]